---
title: "Reviews — fexofenadine 60mg - Flapen"
canonical_url: "https://flapen.com/research/us/health-household/fexofenadine-60mg/reviews"
last_updated: "2026-08-11T21:55:50.374Z"
locale: en
meta:
  description: "Niche score 58/100 · $575K/yr market. A failed launch gate (market size, growth, or returns) keeps it on the watch list. Data updated Jul 2026."
  "og:description": "Niche score 58/100 · $575K/yr market. A failed launch gate (market size, growth, or returns) keeps it on the watch list. Data updated Jul 2026."
  "og:title": "Reviews — fexofenadine 60mg - Flapen"
---

# **fexofenadine 60mg**

**Worth a look**

Shows low returns (0.0%), but a failed launch gate (market size, growth, or returns) keeps it on the watch list.

Market size 63Growth 71Conversion 96Competition 27Returns 100Price range 86Avg price 95Brand share 6Review moat 45Quality gap 19

**Returns**

**Incredible****0.0%**

return rate — above 5% kills the launch gate

**Conversion**

**Incredible****12.8%**

search→purchase rate — share of searches ending in a sale

**Avg price**

**Incredible****$25.77**

avg listing price — sweet spot $15–$100

**Price range**

**Great****$8.93–$65.38**

cheapest to priciest tracked listing — scored on the share inside $15–$100

**Growth**

**Good****+53.4%**

90-day search growth — must beat 0% to launch

**Market size**

**Good****$575K**

$575K/yr · 174K searches

**Review moat**

**Okay****2,031.57**

avg incumbent reviews — the moat a new listing must climb

**Competition**

**Okay****69%**

top-5 click share — leaders hold, buyers still browse

**Quality gap**

**Bad****4.7★**

avg incumbent rating — lower means beatable quality

**Brand share**

**Bad****97%**

top-5 brand share — brand-locked demand

## Reviews